Smith & Nephew plc (SNN)
| Market Cap | 10.74B |
| Revenue (ttm) | 5.64B |
| Net Income (ttm) | 305.00M |
| Shares Out | 873.47M |
| EPS (ttm) | 0.35 |
| PE Ratio | 35.22 |
| Forward PE | 13.56 |
| Dividend | $0.75 (2.98%) |
| Ex-Dividend Date | Oct 4, 2024 |
| Volume | 614,367 |
| Open | 25.18 |
| Previous Close | 25.51 |
| Day's Range | 25.02 - 25.24 |
| 52-Week Range | 23.65 - 31.72 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Aug 1, 2024 |
About SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other... [Read more]
Financial Performance
In 2023, Smith & Nephew's revenue was $5.55 billion, an increase of 6.40% compared to the previous year's $5.22 billion. Earnings were $263.00 million, an increase of 17.94%.
Financial StatementsNews
Big investors call for break-up of Smith & Nephew, FT reports
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenti...
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Par...
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its su...
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design ...
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-ma...
This stock is 'boring' but has 'fantastic' risk-reward: Scharf
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors.
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Desig...
Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help...
Smith & Nephew Delivering On Its Turnaround Promise
The Street has taken notice of Smith & Nephew's turnaround progress, with better than expected revenue and margin results driving share price outperformance. While the ortho business has continued to ...
Smith & Nephew plc (SNN) Q2 2024 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN) Q2 2024 Results Conference Call August 1, 2024 2:00 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Cal...
Smith & Nephew shares rise as profit beats market forecast
Smith & Nephew's shares rose 9% on Thursday after the British medical equipment maker's half-year profit beat market forecast, helped by a strong performance in its orthopaedics segment.
Activist Cevian has a stake in medical device company Smith & Nephew. How it may help improve margins
British company Smith & Nephew is already a global leader in medical tech. Cevian could help it boost its profitability.
Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
Shares of Smith & Nephew Plc SNN are trading higher on Friday. Smith+Nephew offers a medical technology portfolio across orthopedics, sports medicine, ENT, and advanced wound management.
Smith & Nephew shares surge as activist Cevian Capital reveals 5% stake
Activist investor Cevian Capital on Thursday revealed it has built up a 5% stake in British medical equipment seller Smith & Nephew, causing shares in the struggling FTSE-100 company to surge.
U.K. Top 40 Quality Dividend Stocks: Summer 2024
Unfortunately, UK investors have had to suffer weak or negative capital gains in recent years to get those high yields. The good news is that the UK remains an attractive market for dividend investors...
Smith & Nephew: Work To Be Done But Still Long-Term Potential
Smith & Nephew's share price has increased by 14% since September 2022, indicating undervaluation. The company showed decent top line growth with a 6.4% increase in revenue last year. While the compan...
Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript
Smith & Nephew plc (NYSE:SNN) Q1 2024 Sales/Trading Statement Conference Call May 1, 2024 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer C...
U.K. Top 40 Quality Dividend Stocks: Q2 2024
The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yi...
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, anno...
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE)...
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centr...
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial ar...
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use wit...